Search research articles
Contact Us
Filters
Showing results (11-20 of 13) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 13 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
Tomer Mark, Jessica Stern, Jessica R Furst, et al.
British Journal of Haematology
|
August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy
Ruben Niesvizky, Tara Naib, Paul J Christos, et al.
Blood
|
November 9, 2007
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
Ruben Niesvizky, David S Jayabalan, Paul J Christos, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 13) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 13 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
Tomer Mark, Jessica Stern, Jessica R Furst, et al.
British Journal of Haematology
|
August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy
Ruben Niesvizky, Tara Naib, Paul J Christos, et al.
Blood
|
November 9, 2007
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
Ruben Niesvizky, David S Jayabalan, Paul J Christos, et al.
Page
of 2